{"id":774981,"date":"2023-08-03T07:12:27","date_gmt":"2023-08-03T11:12:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/"},"modified":"2023-08-03T07:12:27","modified_gmt":"2023-08-03T11:12:27","slug":"verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/","title":{"rendered":"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Aug.  03, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dmW9PNy_1rSo8yRNEBvZI6rhZ_5u95QcFDadD5qgcczPVF7a9jScq5AX5-u8EZWmEMic1Zd1VioIbx50geRt6nvJ3N0GkBKGCvb1zYjf340=\" rel=\"nofollow noopener\" target=\"_blank\">Verve Therapeutics<\/a>, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Canaccord 43<sup>rd<\/sup> Annual Growth Conference on Thursday, August 10, 2023 at 11:30 a.m. ET in Boston.<\/p>\n<p>A live webcast will be available in the investor section of the company&#8217;s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.<\/p>\n<p>\n        <strong>About Verve Therapeutics\u00a0<\/strong><br \/>\n        <br \/>Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company\u2019s initial three programs \u2013 VERVE-101, VERVE-102, and VERVE-201 \u2013 target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and ultimately to treat patients with refractory hypercholesterolemia. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q5acit6FjqgjmZqpyG2CBBpk1r_J3uZ2AXD0ixYFDhCD0XaZrJhhopABZKNdzDMkmFKnG1bLHpuiX7BjeJSs1w==\" rel=\"nofollow noopener\" target=\"_blank\">www.VerveTx.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Jen Robinson<br \/>Verve Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vUk6DzIqdUwwoOzniJLmWbT1Mt_IdeU0eV5EqnWghNP5dYFm-T-tzcYFUj6O7kVWzpOgtVP9Liu9DZU0NoKyhon7GQTsvRkJPYdpe21PGkTT_694wTH6hr4pSHUg0zEMUTqYYFBO01lJJS0db_n5dnAmWDRzdz_moZ-fRPa6lF1SysqEQH9ZESDEGeTAXve5CjLixmauCKSWry1LgkQYvzqQKro2zEKWsArK0xE1CyC6bwbLvvJR87rOAvEIz7xerCNgUEMpkpKK5p7yY8gXFA==\" rel=\"nofollow noopener\" target=\"_blank\">jrobinson@vervetx.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Ashlea Kosikowski<br \/>1AB<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vA0yKXYbsvBpFOsit-2v4FVodUthkMbPbIbbYVlAdBo3w_D__kE9afKMiKTnTNVuvbbv5eBo5jN81wE8HrRwS5G6vO-rDrPYtz1GGNs-eVgqGK8ibO-Ms4dz7GwK6DhyVVmSGqDooZvxrxG47YrAZXneWDbQ4BjehXSxpeucqU6Lodi1E5xgQBGeEy9t8GfU9iTfv8IuJTz_CdSQDkLOpn6MThvy1S5_bVpRXlIuQAsJu2V5Mdj8cfFmKLvdY7t2x8lyRezTMsKfgzqhiUEVGg==\" rel=\"nofollow noopener\" target=\"_blank\">ashlea@1abmedia.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Nzk5NDBmYzktMDNhOC00YTFjLWI5MGMtMTM4YjhkYTI2MTU0LTEyMTUyNzM=\/tiny\/Verve-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) &#8212; Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Canaccord 43rd Annual Growth Conference on Thursday, August 10, 2023 at 11:30 a.m. ET in Boston. A live webcast will be available in the investor section of the company&#8217;s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation. About Verve Therapeutics\u00a0 Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-774981","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) &#8212; Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Canaccord 43rd Annual Growth Conference on Thursday, August 10, 2023 at 11:30 a.m. ET in Boston. A live webcast will be available in the investor section of the company&#8217;s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation. About Verve Therapeutics\u00a0 Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing &hellip; Continue reading &quot;Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-03T11:12:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference\",\"datePublished\":\"2023-08-03T11:12:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/\"},\"wordCount\":257,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/\",\"name\":\"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=\",\"datePublished\":\"2023-08-03T11:12:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference - Market Newsdesk","og_description":"BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) &#8212; Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Canaccord 43rd Annual Growth Conference on Thursday, August 10, 2023 at 11:30 a.m. ET in Boston. A live webcast will be available in the investor section of the company&#8217;s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation. About Verve Therapeutics\u00a0 Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing &hellip; Continue reading \"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-03T11:12:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference","datePublished":"2023-08-03T11:12:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/"},"wordCount":257,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/","name":"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=","datePublished":"2023-08-03T11:12:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ0MSM1NzM0OTE4IzIyMDM3MjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verve-therapeutics-to-present-at-the-canaccord-43rd-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/774981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=774981"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/774981\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=774981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=774981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=774981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}